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Oxaliplatin with infusional 5-fluorouracil plus leucovorin (FOLFOX regimen) is the one of the standard chemotherapy 
regimens for treating a colorectal carcinoma. The most common side effects include neutropenia, diarrhea, vomiting and 
peripheral neuropathy, and these are moderate and manageable. However, pulmonary toxicity is rarely reported to be as-
sociated with the FOLFOX regimen. Moreover, there is no established guideline for the management of this side effect. 
Here, along with a literature review, we report two cases of rapidly developing pulmonary fibrosis related to the use of the 
FOLFOX regimen in patients with colorectal carcinomas.
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CT, the tumor was shown to be located on the recto-sigmoid junc-
tion, with multiple lymph-node metastases on the left supra-clavic-
ular, para-vertebral and para-aortic areas and with no hepatic or 
pulmonary metastasis. Under the diagnosis of recto-sigmoid colon 
cancer with multiple distant metastases of lymph nodes, a laparo-
scopic-assisted anterior resection was performed in that hospital. 
The pathology result for a specimen showed a moderately differ-
entiated adenocarcinoma that had infiltrated the pericolic adipose 
tissue. Lymphatic, perineural and venous invasions were presented. 
Metastases of regional lymph nodes were found in 16 out of the 
20 retrieved pericolic lymph nodes. The final pathologic stage was 
T3N2bM1, stage IV. After recovering from surgery, the patient vis-
ited our hospital for palliative treatment. FOLFOX-4 regimen (ox-
aliplatin with infusional 5-fluorouracil plus leucovorin)[1] was cho-
sen and started in June 2010; targeted agents were not included 
because of the economic situation of the patient. Except for inter-
mittent grade-3 neutropenia, the patient tolerated FOLFOX-4 
chemotherapy well.
On the follow-up CT after the 12th cycle of chemotherapy, the 
multiple lymph-node metastases on the left supra-clavicular, para-
vertebral, and para-aortic areas had disappeared. Two weeks fol-
lowing the end of 13th cycle of chemotherapy, dry cough and dys-
pnea developed, and the symptoms rapidly worsened. On the 28th 
day after 13th cycle of chemotherapy, he visited the hospital due 
to pulmonary symptoms. Vital signs were stable with normal body 
temperature. On physical examination, dyspnea on exertion was 
presented, and inspiratory crackles were audible on both lungs. 
There was no chest retraction, wheezing or cyanosis. On arterial 
blood gas analysis (ABGA), a pH of 7.41, a PaCO2 of 27.8 mmHg 
and a PaO2 of 86.9 mmHg were shown in room air. The chest X-
INTRODUCTION
Oxaliplatin-based chemotherapy, including the FOLFOX regimens 
has been widely used to treat colorectal cancer. However, there have 
been rare reports of pulmonary toxicity associated with FOLFOX 
regimen. Here, we report two cases of rapidly developing to pul-




A 55-year-old man had visited another hospital in May 2010 with 
presenting symptoms of low abdominal pain and bowel habit 
change for several months. He had no history of smoking, hyper-
tension, diabetes mellitus, hepatitis or pulmonary disease. Colonos-
copy showed a recto-sigmoid colon tumor. Colonoscopic biopsy 
revealed a moderately differentiated adenocarcinoma. On com-
puted tomography (CT) and positive emission tomography (PET)/
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ray and high-resolution chest computed tomography (HRCT) dem-
onstrated parenchymal distorsion, fibrosis and multiple patchy 
ground-glass opacities on both lungs (Fig. 1).
Under the suspicion of oxaliplatin-induced pulmonary toxicity, 
idiopathic pulmonary fibrosis, he was admitted and received broad-
spectrum antibiotics and oral corticosteroid immediately. For the 
differential diagnosis with infectious pneumonia and malignant 
disease, bronchoscopy was performed. On bronchoscopic exami-
nation, there was no endobronchial lesion, and no other infection 
or malignancy was shown on bronchoscopic biopsy or bronchoal-
veolar lavage cytology. The bronchial washing culture was also neg-
ative. At the beginning of the treatment, the patient had felt better 
in terms of dyspnea. However, after two days of hospitalization, 
the dyspnea worsened; in spite of the medical treatment, the dif-
fuse ground-glass opacities the on chest X-ray had progressed. On 
the 3rd hospital day, the patient was moved into the intensive care 
unit (ICU) and intubated, and mechanical ventilation was started. 
Steroid therapy was changed to intravenous methylprednisone, but 
the patient showed a poor clinical course and progressively wors-
ening radiographic findings. On the 23rd hospital day, he died due 
to irreversible respiratory failure and multiple organ failure.
Case 2
A 73-year-old man with hepatic flexure colon cancer was referred 
to the Department of Surgery for operation. He had a medical his-
tory of noninsulin-dependent diabetes mellitus without complica-
tions and no history of cigarette smoking. A right hemicolectomy 
was performed for colon cancer on the hepatic flexure in July 2009. 
Pathology showed a moderately differentiated adenocarcinoma 
that had infiltrated the pericolic adipose tissue. Lymphatic, peri-
neural and venous invasions were not presented. Metastasis of a 
regional lymph node was found in 1 out of 34 retrieved pericolic 
lymph nodes. The final pathologic stage was T3N1M0, stage IIIB. 
A chest X-ray and chest CT before the initiation of chemotherapy 
showed an emphysematous lung on both upper lobes and the right 
middle lobe, but no pulmonary symptoms were present (Fig. 2). 
Adjuvant chemotherapy, including the FOLFOX-4 regimen, was 
started in September 2009. There were no specific changes on fol-
low up after every three cycles of chemotherapy, including CT and 
Fig. 1. High-resolution chest computed tomography showing the pa-
renchymal distorsion, the fibrosis and multiple patchy ground-glass 
opacities on both lungs.
Fig. 2. High-resolution chest computed tomography before the initi-
ation of oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX) treat-
ment. There is underlying emphysema on both upper lungs.
Fig. 3. High-resolution chest computed tomography. There are ground-
glass areas on both lower lungs and a patchy consolidation on the right 
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tumor markers, during the course of the treatment.
During the 9th cycle of the FOLFOX-4 regimen, immediately 
after the administration of oxaliplatin, dyspnea suddenly devel-
oped on the 1st hospital day. At the time, the body temperature 
was 39.3°C. Pulmonary auscultation revealed inspiratory crackles 
in both lungs, and dyspnea on exertion was presented. Leukocy-
tosis (23.63 × 10
3/µL) with a predominance of neutrophils (94.5%) 
was noted on the laboratory test. C-reactive protein was elevated 
at 16.89 mg/dL (reference range, <0.5 mg/dL). A chest X-ray and 
HRCT showed ground-glass opacities in the left upper lobe and 
both lower lobes, and a patchy consolidation in the right middle 
lobe (Fig. 3). A treatment with oxygen therapy with a mask, corti-
costeroids and broad-spectrum antibiotics were started. Sputum 
and blood cultures were negative. On the test for the Swine influ-
enza A virus, which we conducted because of a flu epidemic at the 
time, virus infection was negative. Based on the clinical course and 
imaging findings, we made a diagnosis of FOLFOX-induced inter-
stitial pneumonitis or hypersensitivity pneumonia. He presented 
with progressive respiratory failure and was transferred to the ICU 
for mechanical ventilation on the 11th hospital day. The clinical 
course was unfavorable, with worsening of respiratory insufficiency, 
leading to the patient’s death on the 18th hospital day.
DISCUSSION
Oxaliplatin-containing regimens, including the FOLFOX regimens 
have become a part of the standard treatment in a high number of 
colorectal-cancer patients with regional lymph-node metastasis 
for adjuvant setting and advanced stage [2]. The major toxicity of 
oxaliplatin is a peripheral neuropathy. Renal, haematological and 
gastrointestinal toxicities are less frequent [3]. To our knowledge, 
oxaliplatin-induced pulmonary toxicity is rare [4], so there is no 
established guideline for its management.
We experienced two fatal cases with interstitial pneumonitis rap-
idly progressing to pulmonary fibrosis during FOLFOX-4 chemo-
therapy. Muneoka et al. [5] reported a case of FOLFOX-induced 
interstitial pneumonitis, which did not recur after the reintroduc-
tion of 5-fluorouracil/leucovorin alone. However, Yague et al. [3] 
reported interstitial lung disease after oxaliplatin monotherapy (85-
mg/m
2 D1 intravenous in a 2-hour infusion every 3 weeks). There-
fore, the main cause of FOLFOX-regimen-induced interstitial pneu-
monitis is thought to be oxaliplatin. Several case reports of oxali-
platin-induced pulmonary fibrosis have been reported. The details 
of those cases are shown in Table 1. The manifestations of drug-
induced pulmonary toxicity are usually nonspecific, so an accu-
rate diagnosis is difficult.
Once oxaliplatin-induced interstitial pneumonitis has occurred, 
cessation of oxaliplatin is mandatory [5]. High-dose corticosteroid 
treatment is commonly given for serious cases. However, the role 
of high-dose corticosteroid treatment in the management of oxali-
platin-induced interstitial pneumonitis remains unclear [5]. Of the 
14 cases reported in Table 1, 13 patients were treated with high-
dose corticosteroid, but 5 of the treated patients died. The median 
number of cycles of FOLFOX and the median dose of oxaliplatin 
were 6 cycles (range, 4 to 6 cycles) and 510 mg/m
2 (range, 340 to 
780 mg/m
2) in the patients who died and 13 cycles and 1,105 mg/
Table 1. Reported cases of oxaliplatin-induced pulmonary fibrosis
             Author Sex/Age No. of cycles
Total dose  
(mg/m
2)
Primary lesion Steroid treatment Result
  1 Trisolini et al. [8] M/60   7 910 Rectum Given Improved
  2 Gagnadoux et al. [6] F/60   8 680 Colon None Improved
  3 Yague et al. [3] F/68   6 780 Colon Given Dead
  4 Ruiz-Casado et al. [9] M/67 11 1,100 ? Given Improved
  5 Pasetto and Monfardini [4] M/74   6 510 Sigmoid Given Dead
  6 Garrido et al. [10] F/30   6 510 Rectum Given Improved
  7 Arevalo et al. [2] M/73   4 340 Sigmoid Given Dead
  8 Arevalo et al. [2] M/71   4 340 Sigmoid Given Dead
  9 Wilcox et al. [7] M/71   6 510 ? Given Dead
10 Wilcox et al. [7] M/77 12 1,020 Colon Given Improved
11 Wilcox et al. [7] M/69   6 510 Colon Given Improved
12 Ohori et al. [11] M/69 10 850 Colon Given Improved
13 Ohori et al. [11] M/72 11 935 Colon Given Improved
14 Muneoka et al. [5] M/82 10 850 Colon Given Improved
15 Case 1 M/55 13 1,105 RS Given Dead
16 Case 2 M/73   8 680 HF Given Dead
RS, rectosigmoid; HF, hepatic flexure.Journal of The Korean Society of
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m
2 in case 1 and 8 cycles and 680 mg/m
2 in case 2, respectively. 
Although there were slight differences in the median numbers of 
cycles of FOLFOX and the median doses of oxaliplatin, some cases 
had a rapid and untoward course [2-4, 6, 7], similar to what oc-
curred in our cases.
Our patients had a rapidly progressive respiratory insufficiency, 
needed mechanical ventilation on the 3rd day of admission in 
case 1 and on the 8th day of admission in case 2, were refractory 
to conventional high-dose corticosteroid treatment, had a poor 
clinical and radiographic course, and eventually died on the 23rd 
hospital day in case 1 and on the 18th hospital day in case 2 respec-
tively. Even though interstitial pneumonitis is rare in patients treated 
with the FOLFOX regimen, we recommend careful monitoring of 
drug-induced pulmonary toxicity, which may occur in patients 
during or at the end of oxaliplatin chemotherapy.
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